Clinical Trials Logo

Subarachnoid Hemorrhage clinical trials

View clinical trials related to Subarachnoid Hemorrhage.

Filter by:

NCT ID: NCT05604404 Recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Effects of Head-of-Bed on Intracranial Pressure

Start date: April 24, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate how pressure inside the skull responds to position changes in patients with brain bleeds.

NCT ID: NCT05560373 Not yet recruiting - Clinical trials for Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage

The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study

Start date: September 30, 2022
Phase: Phase 4
Study type: Interventional

Under the premise of basic treatment, to explore the improvement effect of huperzine A injection on short-term and long-term neurocognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage after interventional/surgical treatment.

NCT ID: NCT05499806 Enrolling by invitation - Clinical trials for Traumatic Brain Injury

Cohort Study on the Effects of Aging in Acquired Brain Injury Patients

BRAINReADAPT
Start date: March 18, 2022
Phase:
Study type: Observational [Patient Registry]

A prospective cohort study (questionnaires), with an embedded case control study (neuropsychological assessments) in which the data is gathered within a timeframe of 3 years. A group of 700 patients and a group of 100 healthy volunteers will be participating.

NCT ID: NCT05491980 Recruiting - Ischemic Stroke Clinical Trials

Florida Cerebrovascular Disease Biorepository and Genomics Center

Start date: August 2, 2022
Phase:
Study type: Observational

The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from subjects affected by cerebrovascular disease. The information and blood samples collected may be used in future research for the study of cerebrovascular disease and to learn about, prevent or treat other health problems.

NCT ID: NCT05483751 Recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Micro- and Macrovascular Parameters in Delayed Cerebral Ischemia

PDMMS
Start date: January 1, 2023
Phase:
Study type: Observational

Delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH) results from a complex combination of macro- and microvascular processes. Besides cerebral vasospasms (CVS), DCI is caused by microthrombosis, neuroinflammation, microvascular dysfunction and cortical spreading depolarization.The glycocalyx plays an essential role in regulation of inflammation, oxidative stress and thrombosis, and could be involved in the pathophysiology of DCI. This study is a single-center prospective observational pilot (phase 1) and correlation (phase 2) study recruiting patients with an aneurysmal subarachnoid hemorrhage. The primary aim of the study is to evaluate the feasibility of performing measurements of the glycocalyx using side-stream darkfield (SDF) imaging sublingually and on the conjunctiva, and by sampling blood for analysis of markers of glycocalyx shedding. Moreover, the objective is to determine characteristic Doppler waveform morphologies in DCI patients by means of thorough analysis of transcranial Doppler (TCD) measurements. The secondary objective is to determine whether changes in glycocalyx integrity correlate with the development of DCI and whether these changes are associated with increased inflammation and with variation in TCD signals. Finally, changes in glycocalyx integrity, in TCD waveform morphology and in levels of inflammatory markers will be correlated with patient outcome at 6 weeks and 6 months after ictus.

NCT ID: NCT05450939 Recruiting - Aneurysmal Rupture Clinical Trials

Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture

Start date: November 25, 2021
Phase:
Study type: Observational

10-20% of patients with subarachnoid hemorrhage die before they arrive at the hospital, and about 25% die within 24 hours. About 1% of patients are diagnosed with cerebral aneurysms in imaging tests for health checkups, and many of them experience aneurysmal rupture during their lifetime, so it is not a rare disease. Wall shear stress is known to be a factor that reflects the state of blood vessels, and particularly plays an important role in the patency of the intima of blood vessels. In the meantime, computed fluid dynamics (CFD), a representative method for calculating wall shear stress, assumes a virtual rigid pipe and applies a preset value. This does not accurately reflect the physiological and dynamic state of the actual blood vessel. The investigators intend to measure the patient's wall shear stress using the SIG of the MRA-TOF technique, which reflects the physiological characteristics of individual patients, and to analyze the association with rupture of the intracranial aneurysm.

NCT ID: NCT05418348 Completed - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

Start date: August 26, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single center, randomized, two-period crossover study in healthy male and female subjects designed to evaluate the relative bioavailability (BA) and safety at steady state of two formulations of nimodipine: GTX 104 (nimodipine for intravenous [IV] infusion; test formulation) and nimodipine oral capsules, RS (reference formulation).

NCT ID: NCT05408988 Recruiting - Clinical trials for Subarachnoid Hemorrhage

Neurogenic Myocardial and Lung Injury in SAH Patients

Start date: January 22, 2022
Phase:
Study type: Observational

Up to this day, little is known whether the extent of brain damage in patients with SAH correlates with the degree neurogenic myocardial injury and neurogenic lung injury. This is a prospective observational study designed to asses relationship between catecholamine surge and development of myocardial and lung injury in subarachnoid haemorrhage patients.

NCT ID: NCT05403970 Recruiting - Clinical trials for Subarachnoid Hemorrhage

Correlation of Various Laboratory Parameters With Outcome in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage - Prospective Case Series

Start date: June 1, 2022
Phase:
Study type: Observational

In this prospective study, the investigators aim to investigate the effect of the following three factors on the development of vasospasm and patient outcome: (1.) the role of anemia; (2.) the role of plasma fibrinolytic activity; (3.) the role of vitamin D. The investigators include patients admitted to the Neurosurgical Intensive Care Unit of the Clinical Center of the University of Debrecen with the diagnosis of subarachnoid hemorrhage (SAH). Patients are treated according to international guidelines. As part of the study protocol the following investigations are performed: • Hemoglobin level measurement: on the day of admission and day 3-4-7 and 14 after hemorrhage •Modified clot lysis assay (mCLA): on the day of admission and day 7 after hemorrhage •25-hydroxy vitamin-D level measurement: on the day of admission •Transcranial color-coded duplex sonography (detecting vasospasm): on daily basis. •30 day follow-up: mortality, Glasgow Outcome Scale (GOS), Karnofsky score, Barthel score •90 day follow-up: mortality, Glasgow Outcome Scale , Karnofsky score, Barthel score. Laboratory test results are correlated with (a) the development of vasospasm; (b) with 30 and 90 day outcome. Perspectives of the planned study: Considering the currently available therapeutic range for patients with SAH, results of the present study may provide a basis for designing further randomized, prospective trials to investigate the effect of treating anemia, anticoagulation and vitamin-D supplementation.

NCT ID: NCT05298436 Recruiting - Stroke Clinical Trials

The South London Stroke Register: Improving the Lives of Stroke Survivors With Data

SLSR
Start date: April 1, 2022
Phase:
Study type: Observational [Patient Registry]

The South London Stroke Register (SLSR) is an observational population based registry, combining a population incidence study of stroke events in a geographically defined area of South London and a cohort study of these patients followed up over time. The SLSR has been continually ongoing since January 1995 using the WHO ICD-10 definition of stroke. From April 2022, SLSR will use the new ICD-11 definition for case identification to establish a new prospective cohort of patients identified according to the new definition. Follow up of the existing retrospective cohort of current patients will continue, providing data on long term outcomes of stroke through a program of regular patient interviews up to 15 years after stroke. Outcome measures include health outcomes, such as stroke mortality and recurrence, and measures of activities of daily living, quality of life and mental health (cognition, anxiety, depression). The new data collection will include newly selected scales to best capture variation in key health domains and long term outcomes. The change to ICD-11 is expected to lead to an increase in the incidence of stroke and a reduction in the average severity, but the effects of this change have not yet been measured in any population internationally. There is a need for a high quality population-based stroke incidence study to address this gap. Similarly, the factors determining the health of long-term stroke survivors can only be understood using a long running observational cohort study. The overall purpose of this research is to continue and develop the SLSR data collection and analysis to address the needs of stroke patients in the 2020s. The current programme was funded to address the following objectives as part of a broader NIHR programme grant on using data to improve the lives of stroke survivors: - Understand the impact of the ICD-11 new definition of stroke - Define the outcomes and needs of long-term stroke survivors - Support stroke survivors and stakeholders with these detailed data and analyses - Describe the use of formal, informal, and social care services up to 15 years after stroke - Asses the influence of formal, informal, and social care use on stroke recovery and generate patient-level total costs up to 15 years after stroke